Emerging AI Technologies Revolutionize Patient Education in Rheumatology: Novel Chatbots and Digital Platforms Enhance Disease Understanding and Management
In a groundbreaking series of presentations at the EULAR 2026 Congress, the landscape of patient education and engagement in rheumatology has been transformed by the advent of artificial intelligence-based digital tools. People diagnosed with rheumatic and musculoskeletal diseases (RMD), a diverse group of chronic conditions characterized by inflammation, pain, and tissue damage, traditionally face significant challenges in accessing clear, reliable, and personalized information about their diseases. The integration of advanced AI chatbots, large language models, and dedicated patient-centered platforms provides scalable, user-friendly solutions that promise to address longstanding gaps in health literacy and patient empowerment.
The first major innovation presented involved the development and deployment of ten distinct disease-specific chatbots, meticulously programmed according to current German clinical guidelines for rheumatology. These chatbots operate as interactive AI advisors, allowing patients to pose complex queries about their condition and treatment regimens. The initiative, spearheaded by Johannes Knitza and colleagues, leveraged collaborations with patient advocacy groups and practicing rheumatologists to promote adoption and real-time feedback. The results exceeded expectations: across four months, over 5,000 chatbot interactions were recorded with more than 1,300 individual sessions. User feedback was overwhelmingly positive, with 93% of immediate responses receiving affirmative “likes,” illustrating high perceived value.
A detailed survey of 520 users further underscored the utility of these tools. Notably, 94% of respondents reported having an RMD diagnosis, predominantly rheumatoid arthritis, axial spondyloarthritis, and systemic lupus erythematosus. Additionally, 41% had prior experience using AI-based health tools, and an impressive 86% strongly endorsed the chatbot’s ease of use and clarity. The majority considered the chatbot a beneficial supplement to conventional patient education materials, signaling a shift in how digital health literacy tools are received within this medically complex population. Furthermore, more than half of the participants expressed a clear preference for these chatbots over traditional internet searches, highlighting the advantage of specialized, guideline-based AI over unregulated web content of variable quality.
Complementing these disease-specific chatbots, another pivotal study evaluated the performance of large language models (LLMs) against Google Search for answering real patient queries across connective tissue diseases, including systemic lupus erythematosus, idiopathic inflammatory myopathy, Sjögren’s disease, and systemic sclerosis. This research involved input from both patients and rheumatologists, who assessed the responses on parameters such as empathy, trustworthiness, comprehensibility, and medical accuracy. While Google Search provided largely medically correct information, the LLMs stood out by delivering answers that were more nuanced, empathetic, and easier to understand. Physicians confirmed that the LLM-generated responses consistently met high standards of clinical correctness, marking a crucial advance in AI’s potential role in medical counseling.
Phillip Kremer, a lead investigator in this field, emphasized the importance of integrating these AI technologies with appropriate safety measures and ongoing clinical oversight. He noted that AI tools, when carefully implemented, could effectively complement established educational strategies in rheumatology, enhancing personalized patient support and potentially improving health outcomes. This careful orchestration between machine-generated content and expert human validation is essential to foster trust and ensure clinical safety while harnessing the efficiency and accessibility of AI.
Beyond general information dissemination, these innovations also address highly specific and unmet needs within the RMD community. A notably impactful example is the “Steroids and Me” (Sam) platform, designed to empower patients undergoing glucocorticoid therapy, a cornerstone yet problematic treatment for many inflammatory rheumatic diseases due to its significant side effect profile. Long-term steroid use is associated with numerous adverse events, ranging from metabolic disturbances to bone loss, yet patient education on managing these risks has historically been inadequate.
The Sam platform, developed and validated by Martha Stone and collaborators, offers a unique digital journey tracker that enables patients to monitor steroid-induced side effects in real time and share this information directly with their healthcare providers during follow-up consultations. This interactive, web-based tool incorporates clear, jargon-free educational content including prevalent and less recognized steroid complications, practical prevention strategies, and expert video insights from clinicians. The platform fosters active patient participation in their own care, shifting the dynamic from passive information reception to informed decision-making partnership.
Over its first two years, Sam has registered more than 25,000 users worldwide, many of whom engage deeply with the material, spending an average of 5.4 minutes per session—an engagement duration tenfold higher than typical health websites. These metrics not only signify broad reach but also reflect meaningful patient involvement, addressing a critical educational void. Importantly, Sam is not limited to rheumatology but spans multiple conditions requiring steroid therapy, demonstrating its versatility and potential for wide adoption across medical disciplines.
The future vision for Sam includes integration with clinical outcome assessments in glucocorticoid toxicity trials, providing a comprehensive view of treatment burden from both clinical and patient-reported perspectives. This synergistic approach could yield rich insights to optimize steroid stewardship, mitigate adverse effects, bolster shared decision-making, and ultimately improve both longevity and quality of life for patients with chronic rheumatic diseases.
Collectively, these developments signal a transformative era for patient education in rheumatology, marked by digital innovation, personalized AI interactions, and collaborative patient-provider dialogue. As rheumatic disease complexities continue to evolve, such tools represent vital instruments in bridging gaps in knowledge, enhancing adherence, and elevating standards of care. The promise of AI—embodied in disease-specific chatbots, empathic large language models, and dynamic platforms like Steroids and Me—is to empower patients with the understanding necessary to navigate their health journeys with confidence and clarity.
EULAR’s commitment to fostering excellence in rheumatology education, research, and patient advocacy is exemplified through these advances, reinforcing its mission to reduce the burden of RMDs and improve outcomes across Europe and beyond. As these novel digital resources gain traction, they may well catalyze a broader paradigm shift in chronic disease management—where AI augments human expertise to deliver empathetic, accurate, and accessible healthcare knowledge at scale.
Subject of Research: Development and evaluation of AI-based chatbots and digital platforms for patient education in rheumatology, including large language model performance and glucocorticoid therapy management tools.
Article Title: Emerging AI Technologies Revolutionize Patient Education in Rheumatology: Novel Chatbots and Digital Platforms Enhance Disease Understanding and Management.
News Publication Date: June 2026
Web References:
– https://www.eular.org/en_GB/recommendations-home
– https://www.eular.org/en_GB/eular-press-releases
References:
– Wilhelmi T, et al. Turning Guidelines to Answers: Patient Evaluation of AI-Based Guideline Chatbots in Rheumatology. Ann Rheum Dis 2026; DOI: 10.1136/annrheumdis-2026-eular.D.57.
– Kremer P, et al. Beyond “Dr Google”: Performance of Large Language Models in Patient Counselling for Connective Tissue Diseases. Ann Rheum Dis 2026; DOI: 10.1136/annrheumdis-2026-eular.D.132.
– Stone M, et al. Steroids and Me (Sam): Development and Validation of a Patient-Centered Digital Platform for Glucocorticoid Education and Shared Decision-Making. Ann Rheum Dis 2026; DOI: 10.1136/annrheumdis-2026-eular.D.42.
Keywords: Rheumatology, Rheumatic and Musculoskeletal Diseases, Patient Education, Artificial Intelligence, Chatbots, Large Language Models, Glucocorticoid Therapy, Patient Empowerment, Digital Health Tools, Steroid Side Effects, EULAR, Health Literacy.
